T. Rowe Price Investment Management, Inc. filed Amendment No. 5 to a Schedule 13G with the SEC on November 6, 2026, disclosing its beneficial ownership position in Cabaletta Bio Inc. common stock as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: T. Rowe Price Investment Management, Inc. reported beneficial ownership of 17,250,098 shares of Cabaletta Bio Inc. common stock.
  • Percent of class: The reported holdings represent 8.0% of the class, according to the filing.
  • Sole voting power: The filing states sole voting power over 17,186,616 shares, with shared voting power of 0.
  • Sole dispositive power: Sole power to dispose of 17,250,098 shares is reported, with shared dispositive power of 0.
  • Event date: The date of the event requiring the filing is listed as September 30, 2026.
  • Filer classification: T. Rowe Price Investment Management, Inc. is identified as an investment adviser, organized in Maryland.

T. Rowe Price Investment Management Discloses Position in Cabaletta Bio

According to the filing, T. Rowe Price Investment Management, Inc., headquartered at 1307 Point Street, Baltimore, MD 21231, submitted Amendment No. 5 to Schedule 13G regarding its holdings in Cabaletta Bio Inc. (NASDAQ:CABA), whose principal executive offices are located at 2929 Arch Street, Suite 600, Philadelphia, PA 19104. The securities covered are shares of common stock with CUSIP number 12674W109.

The filing discloses that as of September 30, 2026, T. Rowe Price Investment Management, Inc. beneficially owned 17,250,098 shares, representing 8.0% of the class. Of those shares, the firm reported sole voting power over 17,186,616 shares and sole dispositive power over the full 17,250,098 shares. No shared voting or dispositive power was reported.

The filing includes a certification stating that "the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer." The filing further notes that T. Rowe Price Investment Management, Inc. "expressly denied" that the filing constitutes an admission of beneficial ownership. The statement was signed by Ellen York, Vice President, on November 6, 2026.

What Was Disclosed

T. Rowe Price Investment Management, Inc. filed Amendment No. 5 to Schedule 13G disclosing beneficial ownership of 17,250,098 shares, or 8.0%, of Cabaletta Bio Inc. common stock as of September 30, 2026, with sole voting power over 17,186,616 shares.